Poinciana Advisors Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Poinciana Advisors Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Hold	851	–	–	0.19%	86
2026 Q1	$282K	Hold	851	–	–	0.22%	83
2025 Q4	$338K	Sell	851 -6	-0.7%	-$2.65K	0.27%	65
2025 Q3	$391K	Sell	857 -13	-1%	-$5.29K	0.33%	53
2025 Q2	$284K	Buy	870 +19	+2%	+$5.26K	0.26%	76
2025 Q1	$230K	Sell	851 -10	-1%	-$2.57K	0.24%	77
2024 Q4	$203K	Buy	+861	New	+$226K	0.21%	98

Other funds holding ALNY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Poinciana Advisors Group's ALNY Position: Q2 2026 in Review

Poinciana Advisors Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 851 shares worth $256K. The position accounts for 0.19% of the portfolio, ranked #86.

Poinciana Advisors Group first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $391K in Q3 2025. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Poinciana Advisors Group held 851 shares of Alnylam Pharmaceuticals worth $256K as of Q2 2026.
Poinciana Advisors Group left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.19% of Poinciana Advisors Group's portfolio in Q2 2026, its #86 holding.
Poinciana Advisors Group first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Poinciana Advisors Group's Alnylam Pharmaceuticals position peaked at $391K in Q3 2025.
365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Poinciana Advisors Group's 13F filing for Q2 2026, filed 28 Jul 2026.